When was Herophilus founded?

Herophilus was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is Herophilus located?

Herophilus is headquartered in San Francisco, United States. It is registered at San Francisco, California.

How many employees does Herophilus have?

As of Aug 31, 2026, the latest employee count at Herophilus is 6.

Is Herophilus a funded company?

Herophilus is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Sep 12, 2018.

When was the latest funding round of Herophilus?

Herophilus' latest funding was a $***** Series A round on Sep 12, 2018, with participation from 1 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $4.05B in funding in 2026 to date.

Where does Herophilus rank among its competitors?

Herophilus ranks 734th amongst 2896 active competitors, of which 975 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Herophilus?

Herophilus' top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Herophilus - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of drug discovery platform to treat neurological disorders. The company uses a neuro-drug discovery platform by combining Stem cell-derived organoid models of brain tissue, scaled biology, and machine learning to decode brain disease and develop novel drugs with therapeutic potential. It has developed a pipeline for neurodevelopmental and neurodegenerative diseases.

Website: www.herophilus.com/
Social
Registered Address: San Francisco, California

Key Metrics

Founded Year

2017

Location

San Francisco, United States

Stage

Series A

Total Funding

$25M in 1 round

Latest Funding Round

Series A, Sep 12, 2018, $*****

Investors

Dolby Family Ventures & 4 more

Ranked

734^th among 2896 active competitors

Employee Count

6 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 598 more

View Herophilus' full profile

Herophilus is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
SYSTEM1 BIOSCIENCES, INC. CIN: 815153195 , United States, Active	Dec 31, 1999	-	1 (As on Dec 31, 2024)	-

Herophilus has raised a total funding of $25M over 1 round. Its latest funding round was a Series A round on Sep 12, 2018 for $*****. 1 investor participated in its latest round. Herophilus has 5 institutional investors.

Here is the list of recent funding rounds of Herophilus:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 12, 2018	6196642	Series A	5883474	2144867	7982212	1005863

Access funding benchmarks and valuations. Sign up today!

View details of Herophilus's funding rounds and investors

The founders of Herophilus is Frederic Kerrest.

Here are the details of Herophilus' key team members:

Frederic Kerrest: Co-Founder of Herophilus and founder of 3 other companies, 515 Ventures, PassProtect and Okta. They are also an angel investor in 30 startups.
Contact Info: 1 email address

View details of Herophilus's Founder profiles and Board Members

Herophilus' employee count trend

Herophilus has 6 employees as of Aug 26. Here is Herophilus's employee count trend over the years:

Uncover Herophilus' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Herophilus include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Herophilus, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
734th	Herophilus 2017, San Francisco (United States), Series A	Developer of drug discovery platform to treat neurological disorders	$25M	Dolby Family Ventures, Riot & 3 others	44/100